IP Library Granted Patent US 7,887,798
Granted Patent B2
US 7,887,798 · App. 12/246,621 · Granted Feb 15, 2011

Methods of treating cancer by administering antibodies to CD200

Assignee: Trillium Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,887,798
App. No.
12/246,621
Granted
Feb 15, 2011
Kind
B2
Abstract

Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing graft rejection, fetal loss, autoimmune disease, allergies and in inducing tumor cell growth.

Claims (12)

1. A method of inhibiting or reducing leukemia cell growth comprising administering an effective amount of an antibody that binds to and inhibits a CD200 protein to a cell or an animal in need thereof.

2. A method of inhibiting or reducing leukemia cell growth comprising: determining whether CD200 is upregulated in a subject; and administering to the subject an antibody that binds to and inhibits CD200.

3. A method according to claim 2 wherein the step of administering an antibody comprises administering to the subject a monoclonal antibody that binds to and inhibits CD200.

4. A method of treating a leukemia comprising: determining whether CD200 is upregulated in a subject afflicted with leukemia; and administering to the subject an antibody that binds to and inhibits CD200.

5. A method as in claim 4 wherein the step of administering an antibody comprises administering to the subject a monoclonal antibody that binds to and inhibits CD200.

6. A method according to claim 1 wherein the antibody comprises a humanized antibody.

7. A method according to claim 1 wherein the antibody comprises an Fv, scFv, Fab′ or F(ab′)2 fragment.

8. A method according to claim 2 wherein the antibody comprises a humanized antibody.

9. A method according to claim 2 wherein the antibody comprises an Fv, scFv, Fab′ or F(ab′)2 fragment.

10. A method according to claim 4 wherein the antibody comprises a humanized antibody.

11. A method according to claim 4 wherein the antibody comprises an Fv, scFv, Fab′ or F(ab′)2 fragment.

12. A method according to claim 1 further comprising administering a chemotherapeutic agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2010
From: GORCZYNSKI, REGINALD M.; CLARK, DAVID A.
To: TRANSPLANTATION TECHNOLOGIES INC.
Reel/Frame 023795/0262 →
CHANGE OF NAME Recorded Jan 15, 2010
From: TRANSPLANTATION TECHNOLOGIES INC.
To: TRILLIUM THERAPEUTICS INC.
Reel/Frame 023798/0991 →
Continuity (8)
Continuation 11753908 · May 25, 2007
Continuation 11192123 · Jul 29, 2005
Continuation 09917278 · Jul 30, 2001
Continuation In Part 09570367 · May 5, 2000
Continuation PCTCA9801038 · Nov 6, 1998
Provisional Application 60064764 · Nov 7, 1997
Provisional Application 60222725 · Aug 3, 2000
Related Publication 20090053222A1 · Feb 26, 2009